You are here: Industry Insights > Exscientia

News List

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines WorldPharmaNews
January 21, 2022
Sanofi and Exscientia announced a groundbreaking research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology...
Sanofi and Exscientia to develop AI-driven cancer and immunology medicines Pharmaceutical-Technology
January 11, 2022
Sanofi and Exscientia have entered a research partnership and licence agreement for the development of up to 15 new small-molecule medicines across oncology and immunology.
Exscientia and Sanofi establish research collaboration to develop AI-driven precision engineered medicines ExpressPharma
January 10, 2022
Sanofi and Exscientia recently announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology...
Exscientia and Sanofi collaborate to develop AI-driven precision-engineered medicines pharmatimes
January 07, 2022
The platform integrates primary human tissue samples into early target and drug discovery research.
Exscientia receives $1.5m Gates Foundation grant for AI-designed Covid-19 drugs pharmaceutical-technology
July 09, 2021
UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $1.5m grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners to accelerate the development of a new class of Covid-19 drugs.
Exscientia expands translational capabilities with Allcyte acquisition pharmatimes
June 18, 2021
Oxford, UK-based pharmatech company Exscientia has entered into a binding agreement to acquire artificial intelligence (AI) based precision medicine specialist Allcyte.
Exscientia signs $1.2bn AI drug discovery deal with BMS pharmaceutical-technology
May 21, 2021
Bristol-Myers Squibb (BMS) and Exscientia have signed a partnership agreement to leverage artificial intelligence (AI) for the discovery of small molecule drug candidates in various therapeutic areas, including oncology and immunology.
Alzheimer’s drug designed using Exscientia’s AI technology enters clinic pharmatimes
May 17, 2021
An Alzheimer’s disease drug candidate designed using Exscientia’s artificial intelligence (AI) technology has entered Phase I clinical testing, the company announced May 13.
First AI designed Alzheimer’s drug to enter clinical trials europeanpharmaceuticalreview
May 14, 2021
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
Human trials for world's first AI-designed immuno-oncology drug pharmatimes
April 13, 2021
Exscientia has announced that the world's first artificial intelligence (AI)-designed molecule for immuno-oncology has entered human clinical trials.

Previous page 1 2 Next page